Ignite Creation Date:
2025-12-25 @ 3:21 AM
Ignite Modification Date:
2025-12-26 @ 1:59 AM
Study NCT ID:
NCT05429905
Status:
RECRUITING
Last Update Posted:
2023-03-09
First Post:
2021-12-16
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
Sponsor:
KK Women's and Children's Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-18
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12
Completion Date Type:
ESTIMATED
First Submit Date:
2021-12-16
First Submit QC Date:
None
Study First Post Date:
2022-06-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-07
Last Update Post Date:
2023-03-09
Last Update Post Date Type:
ACTUAL